BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is supported by a stronger fundamental backdrop as VOXZOGO delivered Phase 3 CANOPY-HCH-3 data that beat placebo by 2.33 cm/year in annualized growth velocity, with additional gains in standing height and height Z-score and no treatment-related serious adverse events. The HCH sNDA has already been submitted, and a potential 2027 launch could open a new ~14,000-child global population, while the Yuviwel settlement converts a major litigation overhang into royalty income of 20% in the U.S. and 18% in select ex-U.S. markets through May 2030. Even with one-time acquired IPR&D charges from the Alesta acquisition pressuring 2026 EPS, the company still benefits from monetized IP, modeled YUVIWEL royalties, and an expanding pipeline that supports longer-term earnings growth.

BioMarin Pharmaceutical is facing a deteriorating competitive position in achondroplasia as weekly YUVIWEL and oral infigratinib threaten VOXZOGO’s core new-start franchise, especially in infants where the 52-dose regimen versus 365 injections meaningfully lowers caregiver burden and could accelerate switching. Despite VOXZOGO generating $253M in 2Q26, up 15% quarter over quarter, the company’s growth is increasingly dependent on defending a mature asset against better-dosed alternatives while its next skeletal-dysplasia catalyst does not arrive until the 3Q26 earnings print and potential 2027 launch timing. At the same time, BioMarin carries about $3.5B of debt, only about $1.9B in estimated end-3Q27 cash and equivalents, and faces added regulatory, reimbursement, and pipeline-execution risks that make its outlook fundamentally fragile.